Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma.
Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist would be superior for the clinical treatment of these asthma patients. Forty-six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 microg per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV(1)) = 183 ml, P = 0.051; forced expiratory flow between 25 and 75% of the forced vital capacity (FEF(25-75)) = 0.24 l/s, P = 0.030) as compared with inhaled beclometasone dipropionate. Further trials using PPAR-gamma agonists in steroid-resistant airway disease are indicated.
Department of Respiratory Medicine, Faculty of Medicine, University of Glasgow, Glasgow, UK.
M
M
Spears
I
I
Donnelly
L
L
Jolly
M
M
Brannigan
K
K
Ito
C
C
McSharry
J
J
Lafferty
R
R
Chaudhuri
G
G
Braganza
P
P
Bareille
L
L
Sweeney
I M
IM
Adcock
P J
PJ
Barnes
S
S
Wood
N C
NC
Thomson
D000328:Adult; D001249:Asthma / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D047495:PPAR gamma / Q000819:agonists* / Q000502:physiology; D000077154:Rosiglitazone; D012907:Smoking / Q000009:adverse effects / Q000188:drug therapy* / Q000503:physiopathology; D045162:Thiazolidinediones / Q000008:administration & dosage*
D001993:Bronchodilator Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone